Klabin presents sustainable corrugated board packaging at 25th Hortitec

Ensuring that vaccine vials and their potentially life-changing contents remain safe, sterile and identifiable throughout their tightly controlled supply chain is no easy task, and taking risks is not an option. With the new extended 360 Service offering, Metsä Board, part of Metsä Group, is testing the paperboards and simulating packaging designs used by pharma manufacturers to package and protect vaccine doses, providing absolute confidence that the materials are up to the task. COVID-19 and other vaccines are typically stored and transported in extremely cold conditions, which can be as low as -70 degrees Celsius, before being thawed out ready for administration. The secondary paperboard packaging must be able to withstand these temperature extremes and protect the vials throughout the entire process. When a converter is producing packages for cold-chain transportation they have to be 100% certain that the materials they are using are appropriate. This is where Metsä Board’s in-depth testing and simulation capabilities are extremely valuable for the pharma industry.

Paper has been manufactured in Laakirchen for the past 150 years and now with its entry into the packaging paper market, Laakirchen Papier AG has ushered in a new era. Indeed, the decision to break into the containerboard field will secure the long-term success of the company, as with a volume of 26.4 million t/y and annual growth of between two and three per cent, the strong, European corrugated board market segment offers considerable future potential for the paper industry. Accordingly, the production of lightweight containerboard made entirely from recycled fibres on PM10 started in Laakirchen mid of October. The paper machine meanwhile runs stable and produces paper on A quality level. The PM10 will now manufacture up to 450,000 t/y of containerboard based on recycled paper with working widths of 7.5 m at a speed of 1,600 m/min. This production switch also required additional investments at the company location. These included new plant for the treatment of wastepaper fibres and anaerobic used water cleaning, storage areas for recycling paper, and the completion of a warehouse with an automated crane system for the new products. Click Read More below for additional information.

Aptar Digital Health, a global leader in digital health solutions (Software as a Medical Device (SaMD) and digital Patient Support Programs), connected devices and disease management, today announced a collaboration with SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors and innovative specialty delivery systems. The collaboration will extend SHL Medical’s connected device technologies by integrating Aptar Digital Health’s SaMD platform to provide comprehensive solutions to help patients on injectable therapies manage their disease. As part of this collaboration, devices designed by SHL Medical, such as the Molly® Connected Cap – a smart retrofittable add-on for SHL Medical’s Molly® modular platform autoinjector – will benefit from Aptar Digital Health’s SaMD platform to enhance the patient experience by offering additional support during self-administration via a digital solution.